Title: 

Nucleoside derivative for use as a drug, especially in the treatment of chronic lymphocytic leukemia. 

Protection status: 

Patent No. PCT/IB205/055945 

Subject: 

The subject of the present invention is an antileukemic drug derivative for use against chronic lymphocytic leukemia (CLL). The nucleoside derivative contains a boron cluster attached to the structure of the nucleoside at position 2 or 8 of the purine base via a linking group and its derivatives – 5′ phosphate, thiophosphate or phosphonate. 

Benefits: 

High sensitivity of cancerous peripheral blood mononuclear cells to the nucleoside derivative, with low sensitivity of healthy cells and high pro-apoptotic potential against cancer cells. Also beneficial is the weaker cytotoxic effect of the compounds on healthy cells, compared to currently used drugs. 

Stage of work: 

The compounds were fully characterized by UV, IR, ‘H-, ‘C-, ‘P- and ‘B-NMR , FAB-MS and chromatographic methods – cytotoxicity, ability to induce apoptosis in cancer cells, ability to activate caspase 3 and effects on the protein profile of cancer cells were determined. 

Application: 

Potential use of the compound as a drug, especially in the treatment of chronic lymphocytic leukemia. 

Contact: 

@:  sylwia.grzelak@umed.lodz.pl, tel.: 502 447 575